The FDA advisory committee is evaluating Galleri, Grail’s blood-based Multi-Cancer Early Detection (MCED) test that screens for more than 50 cancer types from a single blood draw. In a trial of nearly 143,000 participants, the study did not meet its primary endpoints for reducing Stage III/IV disease across 12 cancers, but Grail reports increased screen-detected cancers and fewer Stage IV diagnoses and emergency presentations when annual MCED testing was added to standard care. FDA clearance would likely broaden payer coverage, including Medicare, and accelerate competition from rivals such as Abbott’s CancerGuard and experimental tests like CancerSEEK.
FDA Advisory Panel Weighs Galleri Multi‑Cancer Blood Test Today — What You Should Know
Multi-Cancer Early Detection (MCED) testing is a rapidly growing field.getty
Today an advisory committee at the U.S. Food and Drug Administration (FDA) is meeting to consider whether to recommend approval of Galleri, a blood-based Multi-Cancer Early Detection (MCED) test developed by Grail. If approved, Galleri could become the first regulatory-cleared test of its kind to screen for dozens of cancers from a single blood draw.
How Galleri Works
Galleri analyzes fragments of cell-free DNA (cfDNA) in the bloodstream and uses patterns—including DNA methylation signatures—to distinguish signals likely to originate from cancer cells versus healthy tissue. When a cancer signal is detected, the test also attempts to predict the most likely tissue or organ of origin. The approach aims to identify cancers in people who have no symptoms and to complement established single-cancer screening programs.
Key Study Findings
Grail evaluated Galleri in a large trial involving nearly 143,000 participants to assess clinical utility. The trial did not meet its prespecified primary endpoints of a statistically significant reduction in Stage III/IV disease across 12 cancers. However, the company reported that "adding annual MCED testing to standard-of-care cancer screening substantially increased screen-detected cancers and reduced Stage IV cancers and emergency presentations," suggesting fewer late-stage diagnoses and some reduction in clinical burden when MCED testing was added to usual care.
"Adding annual MCED testing to standard-of-care cancer screening substantially increased screen-detected cancers and reduced Stage IV cancers and emergency presentations." — Grail
Why This Matters
Cancer remains the second leading cause of death in the United States and a leading cause worldwide. Recent figures put annual U.S. cancer deaths at roughly 620,000, while breast, lung and bronchus, prostate and colorectal cancers together account for about half of new cases. Earlier detection and timely treatment are critical drivers of improved outcomes, which is why interest in MCED approaches has grown rapidly.
Competitive Landscape
Grail’s Galleri is one of several efforts in the MCED space. Abbott’s CancerGuard similarly monitors DNA methylation and protein biomarkers and markets itself as combining two biomarker classes. Experimental multi-analyte tests such as CancerSEEK combine mutation detection and other blood-based signals. The field is expanding quickly, with multiple companies pursuing complementary technical strategies.
Regulatory And Access Implications
Galleri is already available commercially, but FDA clearance would confer formal regulatory endorsement and likely expand insurance coverage. Approval could make reimbursement through Medicare and other payors more likely, improving patient access and lowering out-of-pocket costs for broader populations.
Looking Ahead
Advisers’ recommendations and FDA decisions will shape how MCED tests are integrated into clinical practice. While competition will intensify, the potential to detect cancers earlier—paired with confirmatory diagnostic pathways—means that innovation in this space could deliver meaningful benefits to patients, clinicians and the healthcare system.
Help us improve.
